DYN Dyne Therapeutics Inc
Price (delayed)
$9.91
Market cap
$1.12B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.37
Enterprise value
$707.63M
Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in
Highlights
DYN's EPS is up by 15% year-on-year and by 5% since the previous quarter
The debt is down by 13% year-on-year and by 3.5% since the previous quarter
DYN's net income is down by 35% YoY and by 8% QoQ
The equity has contracted by 11% from the previous quarter
Key stats
What are the main financial stats of DYN
Market
Valuations
Earnings
Shares outstanding
113.12M
Market cap
$1.12B
Enterprise value
$707.63M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.6
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$343.89M
Net income
-$317.42M
EBIT
-$317.42M
EBITDA
-$315.18M
Free cash flow
-$294.75M
Per share
Balance sheet
Liquidity
EPS
-$3.37
EPS diluted
-$3.37
Free cash flow per share
-$3.13
Book value per share
$6.19
Revenue per share
$0
TBVPS
$7.34
Total assets
$691.23M
Total liabilities
$61.4M
Debt
$23.99M
Equity
$629.84M
Working capital
$617.02M
Debt to equity
0.04
Current ratio
15.6
Quick ratio
15.24
Net debt/EBITDA
1.31
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-45.2%
Return on equity
-49%
Return on invested capital
-138.6%
Return on capital employed
-48.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DYN stock price
How has the Dyne Therapeutics stock price performed over time
Intraday
7.37%
1 week
-11.99%
1 month
-27.19%
1 year
-64.4%
YTD
-57.94%
QTD
-5.26%
Financial performance
How have Dyne Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$343.89M
Net income
-$317.42M
Gross margin
N/A
Net margin
N/A
DYN's operating income is down by 42% YoY and by 9% QoQ
DYN's net income is down by 35% YoY and by 8% QoQ
Growth
What is Dyne Therapeutics's growth rate over time
Valuation
What is Dyne Therapeutics stock price valuation
P/E
N/A
P/B
1.6
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
DYN's EPS is up by 15% year-on-year and by 5% since the previous quarter
The price to book (P/B) is 66% lower than the last 4 quarters average of 4.4 and 53% lower than the 5-year quarterly average of 3.2
The equity has contracted by 11% from the previous quarter
Efficiency
How efficient is Dyne Therapeutics business performance
The return on equity has surged by 64% year-on-year and by 15% since the previous quarter
DYN's return on invested capital has surged by 57% year-on-year and by 18% since the previous quarter
The company's return on assets has surged by 56% YoY and by 12% QoQ
Dividends
What is DYN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DYN.
Financial health
How did Dyne Therapeutics financials performed over time
The total liabilities has declined by 17% year-on-year and by 3% since the previous quarter
The company's total assets fell by 10% QoQ
The debt is 96% smaller than the equity
Dyne Therapeutics's debt to equity has shrunk by 87% YoY
The debt is down by 13% year-on-year and by 3.5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.